Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells 3,000.00 € 4,500.00 €(Discount: 33.33%)
Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs 2,450.00 €
May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals 2,050.00 €
Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry 1,450.00 €